StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for KALV yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $26.81 | $26.76 | -0.19% | 3.5M |
| 05-15 | $26.78 | $26.73 | -0.19% | 8.9M |
| 05-18 | $26.77 | $26.76 | -0.04% | 2.0M |
| 05-19 | $26.75 | $26.77 | +0.06% | 8.0M |
| 05-20 | $26.77 | $26.81 | +0.15% | 5.5M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q3 2025 2025-07-31 |
|---|---|---|---|---|
Revenue | $40.86M | $49.08M | $13.69M | $1.43M |
Operating Income | $-23.44M | $-112.04M | $-154.74M | $-59.01M |
Net Income | $-23.49M | $-109.50M | $-158.91M | $-60.10M |
EPS (Diluted) | $-0.43 | $-2.03 | $-2.97 | $-1.12 |
Total Assets | $328.92M | $335.38M | $339.93M | $215.50M |
Total Liabilities | $348.57M | $338.09M | $322.93M | Not available |
Cash & Equivalents | $213.77M | $229.34M | $243.50M | $124.30M |
Free Cash Flow OCF − CapEx | $-14.58M | $-83.33M | $-128.85M | $-54.79M |
Shares Outstanding | 51.24M | 50.90M | 50.54M | 50.34M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.